Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168797 | 0.88 | TGFBR1 (0.41) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6169733 | 0.86 | PDE3B (0.48) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6167362 | 0.86 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6169245 | 0.83 | PDE3B (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL411631 | 0.83 | TGFBR1 (0.46) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6391672 | 0.82 | DRD2 (0.38) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6168320 | 0.80 | TGFBR1 (0.44) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6168702 | 0.80 | HTT (0.45) | — | |
| SCHEMBL6170719 | 0.79 | HTT (0.58) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL6169255 | 0.79 | HTT (0.48) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | GELLIBERT FRANCOISE J (FR) | 2005-07-28 | — | — | US | claimed |
| EP-1506191-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2003097639-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | claimed |
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | GELLIBERT FRANCOISE J (FR) | 2005-07-28 | — | — | US | disclosed |
| EP-1506191-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097639-A1 | BENZOXAZINE AND BENZOXAZINONE SUBSTITUTED TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165011-A1 | Benzoxazine and benzoxazinone substituted triazoles | ACVR1, TGFBR1, SMAD3 | TGFBR1 2/4885MAPK14 105/4885RIPK2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.